Company intelligence / Profile preview
Krewel Meuselbach
- Ownership
- Private
- Employees
- ~150
- Development stage
- Other
Overview
Krewel Meuselbach develops and markets a range of herbal (plant-derived) medicines, with flagship products like Hedelix® Cough Syrup (ivy leaf extract) showing commercial success. Products are widely distributed in Europe and over 20 countries but do not appear to be subject to ongoing formal clinical trials; they are marketed based on established indications and safety data.
- Therapeutic areas
- Infectious DiseasesPulmonologyNeurology
- Modalities
- PhytopharmaceuticalsSmall molecule
- Industry
- Biotech
Drug pipeline
4 assets3 more assets in the full pipeline.
Partnerships
Beyond the preview
Go deeper on Krewel Meuselbach.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Krewel Meuselbach.